Product Description
Artefenomel, a novel trioxolane, is a front-runner candidate for inclusion in a new antimalarial combination with ferroquine. (Sourced from: https://www.mmv.org/related-story-type/artefenomel)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Sanofi
Company Location: Europe
Company Founding Year: 1973
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Malaria, Falciparum
Phase 2: Malaria, Falciparum|Malaria|Malaria, Vivax|Schistosomiasis haematobia|Coinfection
Phase 1: Malaria, Vivax|Malaria|Healthy Volunteers|Malaria, Falciparum
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03542149 |
QP17C19 | P1 |
Completed |
Malaria |
2019-04-19 |
2024-05-11 |
Primary Endpoints|Treatments |
|
NCT04069221 |
MMV_OZ439_16_01 | P1 |
Completed |
Malaria |
2017-05-30 |
2019-08-30 |
Primary Endpoints |
|
NCT02387580 |
MMV_OZ439_15_001 | P1 |
Completed |
Malaria |
2015-06-01 |
2019-03-20 |
Treatments |
|
NCT02083406 |
MMV_OZ439_13_007 | P1 |
Completed |
Malaria |
2014-07-01 |
2019-03-20 |
Treatments |
|
NCT01958619 |
MMV_OZ439_13_004 | P1 |
Completed |
Malaria |
2014-01-01 |
2019-03-20 |
Treatments |
|
NCT01853475 |
MMV_OZ439_13_002 | P1 |
Completed |
Malaria |
2013-07-01 |
2019-03-19 |
Treatments |
|
NCT01660022 |
MMV_OZ439_12_002 | P1 |
Completed |
Healthy Volunteers |
2013-05-01 |
2019-03-19 |
||
NCT01615822 |
MMV_OZ439_12_001 | P1 |
Terminated |
Malaria |
2013-04-01 |
2019-03-19 |
||
NCT02453581 |
QP12C10 | P1 |
Completed |
Malaria |
2013-03-01 |
2019-03-20 |
||
NCT01713608 |
MMV_OZ439_12_005 | P1 |
Completed |
Malaria |
2013-02-01 |
2019-03-19 |
Treatments |
|
NCT01732588 |
MMV_OZ439_12_003 | P1 |
Completed |
Healthy Volunteers |
2012-12-01 |
2019-03-19 |
Treatments |
|
NCT01383096 |
MMV_OZ439_11_001 | P1 |
Completed |
Malaria |
2012-08-01 |
2019-03-19 |
||
NCT00928083 |
MMV_OZ439_09_001 | P1 |
Completed |
Malaria, Vivax|Malaria, Falciparum |
2009-10-01 |
2019-03-18 |
||
NCT02573857 |
DSMOZ-2 | P2 |
Terminated |
Malaria |
2016-05-01 |
2019-03-20 |
||
NCT04264130 |
SACT | P2 |
Completed |
Coinfection|Schistosomiasis haematobia|Malaria |
2019-12-31 |
2020-02-12 |
Primary Endpoints|Treatments |
|
NCT03660839 |
ACT14655 | P2 |
Completed |
Malaria, Falciparum |
2019-11-06 |
2020-12-03 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date |
|
NCT02497612 |
FALCI | P2 |
Terminated |
Malaria, Falciparum |
2019-09-23 |
2019-11-09 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT02431650 |
OZGAM | P2 |
Completed |
Malaria |
2016-09-01 |
2020-05-29 |
Patient Enrollment|Primary Endpoints|Treatments |
|
NCT02389348 |
OZ/DSMCombo | P2 |
Completed |
Malaria |
2015-06-01 |
2019-03-20 |
Treatments |
|
NCT01713621 |
Extended Observation | P2 |
Completed |
Malaria |
2015-04-01 |
2019-03-19 |
||
ACTRN12612000814875 |
ACTRN12612000814875 | P2 |
Completed |
Malaria |
2013-01-21 |
2026-02-15 |
Treatments |
|
NCT01213966 |
MMV_OZ439_10_002 | P2 |
Completed |
Malaria, Falciparum|Malaria, Vivax |
2012-05-01 |
2019-03-19 |
Treatments |
|
NCT02083380 |
MMV_OZ439_13_003 | P3 |
Completed |
Malaria, Falciparum |
2015-10-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/07/2019 |
News Article |
Sanofi delivers 2018 business EPS growth of 5.1% at CER |